Daily oral GLP-1 medication linked to similar weight loss across three menopausal stages

Дата публикации: 26-09-2026 22:20:01

New analyses to be presented at the annual meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy, Sept. 28–Oct. 2, show that orforglipron, a daily oral medication for weight loss and type 2 diabetes, was associated with similar weight loss among women of different ages and at different life stages: before, during and after menopause.

Основное содержимое страницы с новостью.

Схожие новости

#	Наименование новости	Тональность	Информативность	Дата публикации
1	Diyabet ve obezite ilacında yeni keşif: 'Yaşam süresini ve kalitesini artırabilir'	0	7.43	16-09-2026
2	Enjeksiyon devri kapanıyor mu? İngiltere zayıflama hapına onay verdi	0	11.7	24-08-2026
3	GLP-1 Drugs Not the Most Effective Treatment for Obstructive Sleep Apnea	0	9.78	25-09-2026
4	New evidence supports possible anticancer effects with GLP-1s	0	9.55	18-09-2026
5	El desafío clínico de la era Ozempic’: uno de cada cinco pacientes no pierde ni un 5% del peso con los pinchazos	0	7.17	15-09-2026
6	GLP-1 drugs may help sleep apnea, but CPAP remains best treatment: Study	0	8.6	27-09-2026
7	La otra cara de los fármacos para adelgazar: "Siento la misma hambre que antes, estoy muy decepcionada"	0	9.2	16-09-2026
8	GLP-1 drugs may help sleep apnea, but CPAP remains best treatment: Study	0	8.6	27-09-2026
9	GLP-1 drugs may help sleep apnea, but CPAP remains best treatment: Study	0	8.6	27-09-2026
10	GLP-1 drugs may help sleep apnea, but CPAP remains best treatment: Study	0	8.6	27-09-2026

Классификация: Наука. Схожих патентов: 0. Схожих новостей: 10. Тональность: 0. Информативность: 7.03. Источник: medicalxpress.com.